1. Home
  2. ACRS vs ARL Comparison

ACRS vs ARL Comparison

Compare ACRS & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$3.06

Market Cap

311.0M

Sector

Health Care

ML Signal

HOLD

Logo American Realty Investors Inc.

ARL

American Realty Investors Inc.

HOLD

Current Price

$17.10

Market Cap

279.4M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRS
ARL
Founded
2012
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building operators
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
311.0M
279.4M
IPO Year
2015
1999

Fundamental Metrics

Financial Performance
Metric
ACRS
ARL
Price
$3.06
$17.10
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$9.75
N/A
AVG Volume (30 Days)
1.2M
2.1K
Earning Date
05-27-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
69.01
N/A
EPS
N/A
0.37
Revenue
$1,683,000.00
$47,318,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$46.73
Revenue Growth
N/A
N/A
52 Week Low
$1.05
$9.43
52 Week High
$4.89
$20.00

Technical Indicators

Market Signals
Indicator
ACRS
ARL
Relative Strength Index (RSI) 43.84 54.70
Support Level $2.78 $14.95
Resistance Level $3.46 $17.95
Average True Range (ATR) 0.21 0.36
MACD -0.03 -0.04
Stochastic Oscillator 44.53 50.50

Price Performance

Historical Comparison
ACRS
ARL

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About ARL American Realty Investors Inc.

American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.

Share on Social Networks: